The European Medicine Agency (EMA) on Friday approved the use of the European Union of AstraZeneca vaccines against Kovid-19 for people over 18 years of age.
The vaccine developed by the British laboratory AstraZeneca and the University of Oxford is the third to receive the green light from the EMA on 21 December, followed by Pfizer-BioNtech on 21 December and Moderna on 6 January.
“EMA recommends granting a conditional marketing authorization for the vaccine against Kovid-19 AstraZeneca (…) in 18-year-olds”, announced the European regulator, based in Amsterdam.
The EMA’s decision comes as the pharmaceutical group faced the wrath of European leaders for several days, after explaining that it could only deliver “a quarter” of the promises made to the European Union in the first quarter.
AstraZeneca immediately welcomed the European green light on Friday, promising “broad and reasonable access” to its vaccine.
The EMA said on Friday morning that another vaccine, Pfizer-BioNotech, was related to deaths after vaccination, in which several elderly people were screened. According to the European regulator, “data does not show a link with vaccination” or “safety concerns”.